8G8 Stock Overview
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CS Medica A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.43 |
| 52 Week High | DKK 0.47 |
| 52 Week Low | DKK 0.34 |
| Beta | -1.64 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 15.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8G8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | n/a | -1.2% | 0.9% |
| 1Y | n/a | -17.5% | 5.7% |
Return vs Industry: Insufficient data to determine how 8G8 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 8G8 performed against the German Market.
Price Volatility
| 8G8 volatility | |
|---|---|
| 8G8 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8G8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8G8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Lone Henriksen | www.cs-medica.com |
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis. It offers gels for psoriasis, arthritis, protective nasal, and wound healing; and CBD anti-hair loss serum, as well as sleep nasal sprays and pain patches. The company primarily offers its products under the CANNASEN brand name.
CS Medica A/S Fundamentals Summary
| 8G8 fundamental statistics | |
|---|---|
| Market cap | €6.16m |
| Earnings (TTM) | -€1.76m |
| Revenue (TTM) | €654.98k |
14.3x
P/S Ratio-5.3x
P/E RatioIs 8G8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8G8 income statement (TTM) | |
|---|---|
| Revenue | DKK 4.88m |
| Cost of Revenue | DKK 2.71m |
| Gross Profit | DKK 2.18m |
| Other Expenses | DKK 15.29m |
| Earnings | -DKK 13.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 16, 2024
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 44.60% |
| Net Profit Margin | -268.51% |
| Debt/Equity Ratio | 228.9% |
How did 8G8 perform over the long term?
See historical performance and comparison